Core Viewpoint - The Outsourcing Facilities Association has filed a lawsuit against the FDA, claiming the removal of Eli Lilly's weight loss drug from the shortage list is arbitrary and unlawful, which limits patient access to essential medications [1][2] Group 1: Lawsuit Details - The lawsuit was filed in a Texas federal court, arguing that the FDA's decision restricts patient access to vital treatments [1][2] - The plaintiffs, including FarmaKeio Custom Compounding, assert that the FDA should have provided advanced notice and sought public input before making its decision [2] Group 2: Drug Shortage Context - Eli Lilly's weight loss drug has been in shortage since 2022, prompting the FDA to allow pharmacies to produce cheaper, non-branded versions [1] - The FDA recently declared that the shortage issue has been resolved, which has led to restrictions on the compounding of these drugs by pharmacies [1] Group 3: Implications for Patients - The lawsuit underscores the impact of drug shortages on patient access and raises concerns about the transparency of the FDA's decision-making process [2] - Patients may face higher medication costs or need to seek alternative treatments due to the FDA's recent decision [2] Group 4: Eli Lilly's Response - Eli Lilly is working to improve drug supply, including the construction of a new manufacturing facility in Indiana [2] - Some compounding pharmacies may continue to produce the drug under a federal provision that allows compounding to meet specific patient needs [2]

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.Eli Lilly (LLY 1.27%) stock has climbed in the double digits over the past year thanks to its leading position in one of the highest-growth pharmaceutical markets around: weight loss drugs. Lilly sells tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight control. Doctors have prescribed both for the weight loss indication though, and demand has been so high that it' ...

The drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of promising new medicines and pipeline successes. Obesity drugs of Novo Nordisk and Eli Lilly (LLY) have witnessed tremendous success, which has played a key role in the industry’s outperformance.  Large drugmakers have several robust revenue streams and are mostly profitable companies, which makes them safe havens for investments. Innovation is key to the growth of the industry. Innovation ...

In the latest market close, Eli Lilly (LLY) reached $887.16, with a +0.18% movement compared to the previous day. This move lagged the S&P 500's daily gain of 0.9%. Elsewhere, the Dow gained 0.81%, while the tech-heavy Nasdaq added 1.22%.Shares of the drugmaker have depreciated by 2.98% over the course of the past month, outperforming the Medical sector's loss of 4.05% and lagging the S&P 500's gain of 3.15%.The upcoming earnings release of Eli Lilly will be of great interest to investors. It is anticipated ...

Thursday, The FDA determined the shortage of Eli Lilly And Co’s LLY tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.Tirzepatide injection, branded as Mounjaro and Zepbound, has been in shortage since 2022 due to increased demand.The U.S. health regulator reminded compounders of the legal restrictions on making copies of FDA-approved drugs.The FDA noted that Novo Nordisk A/S‘ NVO semaglutide (Wegovy, Ozempic) is still in shortage.Despite semaglutide being the active ing ...

Eli Lilly and Company (LLY) announced a significant $4.5 billion investment for the establishment of the Lilly Medicine Foundry in Indiana to advance drug production and innovation. This facility will enable the development of new methods for making its drugs and also scale up the supply of medicines for clinical trials for Lilly's growing pipeline. This one-of-a-kind facility, which combines research and manufacturing in a single location, will open in 2027. The Medicine Foundry, which is expected to creat ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Eli Lilly (LLY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Eli Lilly is a member of our Medical group, which includes 1025 different companie ...

The U.S. Food and Drug Administration (FDA) has announced that the supply shortages of Eli Lilly's (LLY, Financial) popular weight-loss and diabetes medications, Zepbound and Mounjaro, have been resolved. This resolution may impact the market presence of generic versions that had become popular due to previous shortages. The initial shortage led the FDA to permit pharmacies to sell less-tested generic versions. Eli Lilly has been increasing investments to boost medication supply, including constructing a ne ...

The U.S. Food and Drug Administration (FDA) recently announced that the shortage of Eli Lilly's weight loss medications, Mounjaro and Zepbound, has been resolved. While these drugs, which contain tirzepatide, are now more readily available, patients and prescribers might still face occasional local shortages as they move through the supply chain.Mounjaro, which is primarily used for diabetes treatment, and Zepbound, used for weight control, had been listed on the FDA's shortage list since late 2022 and Apri ...

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The facility, called the Lilly Medicine Foundry, will house development of new manufacturing methods with an eye toward efficiency. It's a strategy that's already paying off with Lilly's obesity and weight loss drugs Mounjaro and Zepbound, and Lilly wants it to propel the rest of i ...